| __timestamp | Exelixis, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 100244000 |
| Thursday, January 1, 2015 | 96351000 | 29674000 |
| Friday, January 1, 2016 | 95967000 | 14917000 |
| Sunday, January 1, 2017 | 112171000 | 14118000 |
| Monday, January 1, 2018 | 182257000 | 8737000 |
| Tuesday, January 1, 2019 | 336964000 | 6900000 |
| Wednesday, January 1, 2020 | 547851000 | 6248000 |
| Friday, January 1, 2021 | 693716000 | 12312000 |
| Saturday, January 1, 2022 | 891813000 | 19721000 |
| Sunday, January 1, 2023 | 1044071000 | 31283000 |
| Monday, January 1, 2024 | 910408000 |
Unlocking the unknown
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. has demonstrated a robust strategic focus on R&D, with expenditures increasing by over 450% from 2014 to 2023. In contrast, MannKind Corporation's R&D spending has seen a decline, dropping by approximately 69% during the same period. This divergence highlights Exelixis's aggressive pursuit of new therapies, while MannKind appears to be adopting a more conservative approach. The data suggests that Exelixis's strategy may be positioning it for long-term growth and market leadership. As the biotech industry continues to evolve, these investment patterns could significantly impact each company's future trajectory.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Research and Development Expenses Breakdown: Zoetis Inc. vs Exelixis, Inc.
Viatris Inc. or MannKind Corporation: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Exelixis, Inc. and ACADIA Pharmaceuticals Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
Grifols, S.A. vs MannKind Corporation: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Opthea Limited vs MannKind Corporation
R&D Insights: How Catalyst Pharmaceuticals, Inc. and MannKind Corporation Allocate Funds
Research and Development Investment: Mesoblast Limited vs MannKind Corporation
Amphastar Pharmaceuticals, Inc. or MannKind Corporation: Who Invests More in Innovation?
Comparing Innovation Spending: MannKind Corporation and Viridian Therapeutics, Inc.